Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion type Assertion NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_head.
- NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion description "[Although the most widely studied genes are the cell-cycle inhibitors p15INK4b and p16INK4a (specially in AML and ALL), the list of methylation-repressed genes in these neoplasms is expanding very rapidly, including MGMT, RARB2, CRBP1, SOCS-1, CDH1, DAPK1, and others.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_provenance.
- NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion evidence source_evidence_literature NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_provenance.
- NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion SIO_000772 14585279 NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_provenance.
- NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion wasDerivedFrom befree-20150227 NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_provenance.
- NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_assertion wasGeneratedBy ECO_0000203 NP555342.RA5e8j5JZ6ztTiHnr83KQmAR1XEVgV2-GtvSYVL8oYFkc130_provenance.